Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes : A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM Study
Background: SGLT2 inhibitors (SGLT2is) and GLP-1 receptor agonists (GLP1-RAs) reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM). However, their effectiveness relative to each other and other second-line antihyperglycemic agents is unknown, without any major ongoing head-to-head trials.
Methods: Across the LEGEND-T2DM network, we included ten federated international data sources, spanning 1992-2021. We identified 1,492,855 patients with T2DM and established cardiovascular disease (CVD) on metformin monotherapy who initiated one of four second-line agents (SGLT2is, GLP1-RAs, dipeptidyl peptidase 4 inhibitor [DPP4is], sulfonylureas [SUs]). We used large-scale propensity score models to conduct an active comparator, target trial emulation for pairwise comparisons. After evaluating empirical equipoise and population generalizability, we fit on-treatment Cox proportional hazard models for 3-point MACE (myocardial infarction, stroke, death) and 4-point MACE (3-point MACE + heart failure hospitalization) risk, and combined hazard ratio (HR) estimates in a random-effects meta-analysis.
Findings: Across cohorts, 16·4%, 8·3%, 27·7%, and 47·6% of individuals with T2DM initiated SGLT2is, GLP1-RAs, DPP4is, and SUs, respectively. Over 5·2 million patient-years of follow-up and 489 million patient-days of time at-risk, there were 25,982 3-point MACE and 41,447 4-point MACE events. SGLT2is and GLP1-RAs were associated with a lower risk for 3-point MACE compared with DPP4is (HR 0·89 [95% CI, 0·79-1·00] and 0·83 [0·70-0·98]), and SUs (HR 0·76 [0·65-0·89] and 0·71 [0·59-0·86]). DPP4is were associated with a lower 3-point MACE risk versus SUs (HR 0·87 [0·79-0·95]). The pattern was consistent for 4-point MACE for the comparisons above. There were no significant differences between SGLT2is and GLP1-RAs for 3-point or 4-point MACE (HR 1·06 [0·96-1·17] and 1·05 [0·97-1·13]).
Interpretation: In patients with T2DM and established CVD, we found comparable cardiovascular risk reduction with SGLT2is and GLP1-RAs, with both agents more effective than DPP4is, which in turn were more effective than SUs. These findings suggest that the use of GLP1-RAs and SGLT2is should be prioritized as second-line agents in those with established CVD.
Funding: National Institutes of Health, United States Department of Veterans Affairs.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
medRxiv : the preprint server for health sciences - (2024) vom: 08. Feb. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Khera, Rohan [VerfasserIn] |
---|
Links: |
---|
Themen: |
Cardiovascular Diseases |
---|
Anmerkungen: |
Date Revised 09.04.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1101/2024.02.05.24302354 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368608484 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368608484 | ||
003 | DE-627 | ||
005 | 20240409232450.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240219s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2024.02.05.24302354 |2 doi | |
028 | 5 | 2 | |a pubmed24n1370.xml |
035 | |a (DE-627)NLM368608484 | ||
035 | |a (NLM)38370787 | ||
035 | |a (PII)2024.02.05.24302354 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Khera, Rohan |e verfasserin |4 aut | |
245 | 1 | 0 | |a Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes |b A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM Study |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 09.04.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Background: SGLT2 inhibitors (SGLT2is) and GLP-1 receptor agonists (GLP1-RAs) reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM). However, their effectiveness relative to each other and other second-line antihyperglycemic agents is unknown, without any major ongoing head-to-head trials | ||
520 | |a Methods: Across the LEGEND-T2DM network, we included ten federated international data sources, spanning 1992-2021. We identified 1,492,855 patients with T2DM and established cardiovascular disease (CVD) on metformin monotherapy who initiated one of four second-line agents (SGLT2is, GLP1-RAs, dipeptidyl peptidase 4 inhibitor [DPP4is], sulfonylureas [SUs]). We used large-scale propensity score models to conduct an active comparator, target trial emulation for pairwise comparisons. After evaluating empirical equipoise and population generalizability, we fit on-treatment Cox proportional hazard models for 3-point MACE (myocardial infarction, stroke, death) and 4-point MACE (3-point MACE + heart failure hospitalization) risk, and combined hazard ratio (HR) estimates in a random-effects meta-analysis | ||
520 | |a Findings: Across cohorts, 16·4%, 8·3%, 27·7%, and 47·6% of individuals with T2DM initiated SGLT2is, GLP1-RAs, DPP4is, and SUs, respectively. Over 5·2 million patient-years of follow-up and 489 million patient-days of time at-risk, there were 25,982 3-point MACE and 41,447 4-point MACE events. SGLT2is and GLP1-RAs were associated with a lower risk for 3-point MACE compared with DPP4is (HR 0·89 [95% CI, 0·79-1·00] and 0·83 [0·70-0·98]), and SUs (HR 0·76 [0·65-0·89] and 0·71 [0·59-0·86]). DPP4is were associated with a lower 3-point MACE risk versus SUs (HR 0·87 [0·79-0·95]). The pattern was consistent for 4-point MACE for the comparisons above. There were no significant differences between SGLT2is and GLP1-RAs for 3-point or 4-point MACE (HR 1·06 [0·96-1·17] and 1·05 [0·97-1·13]) | ||
520 | |a Interpretation: In patients with T2DM and established CVD, we found comparable cardiovascular risk reduction with SGLT2is and GLP1-RAs, with both agents more effective than DPP4is, which in turn were more effective than SUs. These findings suggest that the use of GLP1-RAs and SGLT2is should be prioritized as second-line agents in those with established CVD | ||
520 | |a Funding: National Institutes of Health, United States Department of Veterans Affairs | ||
650 | 4 | |a Preprint | |
650 | 4 | |a Cardiovascular Diseases | |
650 | 4 | |a Comparative Effectiveness Research | |
650 | 4 | |a Diabetes Mellitus | |
650 | 4 | |a Glucagon-Like Peptide-1 Receptor Agonists | |
650 | 4 | |a Hypoglycemic Agents | |
650 | 4 | |a Sodium-Glucose Transporter 2 Inhibitors | |
650 | 4 | |a Type 2 | |
700 | 1 | |a Aminorroaya, Arya |e verfasserin |4 aut | |
700 | 1 | |a Dhingra, Lovedeep Singh |e verfasserin |4 aut | |
700 | 1 | |a Thangaraj, Phyllis M |e verfasserin |4 aut | |
700 | 1 | |a Camargos, Aline Pedroso |e verfasserin |4 aut | |
700 | 1 | |a Bu, Fan |e verfasserin |4 aut | |
700 | 1 | |a Ding, Xiyu |e verfasserin |4 aut | |
700 | 1 | |a Nishimura, Akihiko |e verfasserin |4 aut | |
700 | 1 | |a Anand, Tara V |e verfasserin |4 aut | |
700 | 1 | |a Arshad, Faaizah |e verfasserin |4 aut | |
700 | 1 | |a Blacketer, Clair |e verfasserin |4 aut | |
700 | 1 | |a Chai, Yi |e verfasserin |4 aut | |
700 | 1 | |a Chattopadhyay, Shounak |e verfasserin |4 aut | |
700 | 1 | |a Cook, Michael |e verfasserin |4 aut | |
700 | 1 | |a Dorr, David A |e verfasserin |4 aut | |
700 | 1 | |a Duarte-Salles, Talita |e verfasserin |4 aut | |
700 | 1 | |a DuVall, Scott L |e verfasserin |4 aut | |
700 | 1 | |a Falconer, Thomas |e verfasserin |4 aut | |
700 | 1 | |a French, Tina E |e verfasserin |4 aut | |
700 | 1 | |a Hanchrow, Elizabeth E |e verfasserin |4 aut | |
700 | 1 | |a Kaur, Guneet |e verfasserin |4 aut | |
700 | 1 | |a Lau, Wallis Cy |e verfasserin |4 aut | |
700 | 1 | |a Li, Jing |e verfasserin |4 aut | |
700 | 1 | |a Li, Kelly |e verfasserin |4 aut | |
700 | 1 | |a Liu, Yuntian |e verfasserin |4 aut | |
700 | 1 | |a Lu, Yuan |e verfasserin |4 aut | |
700 | 1 | |a Man, Kenneth Kc |e verfasserin |4 aut | |
700 | 1 | |a Matheny, Michael E |e verfasserin |4 aut | |
700 | 1 | |a Mathioudakis, Nestoras |e verfasserin |4 aut | |
700 | 1 | |a McLeggon, Jody-Ann |e verfasserin |4 aut | |
700 | 1 | |a McLemore, Michael F |e verfasserin |4 aut | |
700 | 1 | |a Minty, Evan |e verfasserin |4 aut | |
700 | 1 | |a Morales, Daniel R |e verfasserin |4 aut | |
700 | 1 | |a Nagy, Paul |e verfasserin |4 aut | |
700 | 1 | |a Ostropolets, Anna |e verfasserin |4 aut | |
700 | 1 | |a Pistillo, Andrea |e verfasserin |4 aut | |
700 | 1 | |a Phan, Thanh-Phuc |e verfasserin |4 aut | |
700 | 1 | |a Pratt, Nicole |e verfasserin |4 aut | |
700 | 1 | |a Reyes, Carlen |e verfasserin |4 aut | |
700 | 1 | |a Richter, Lauren |e verfasserin |4 aut | |
700 | 1 | |a Ross, Joseph |e verfasserin |4 aut | |
700 | 1 | |a Ruan, Elise |e verfasserin |4 aut | |
700 | 1 | |a Seager, Sarah L |e verfasserin |4 aut | |
700 | 1 | |a Simon, Katherine R |e verfasserin |4 aut | |
700 | 1 | |a Viernes, Benjamin |e verfasserin |4 aut | |
700 | 1 | |a Yang, Jianxiao |e verfasserin |4 aut | |
700 | 1 | |a Yin, Can |e verfasserin |4 aut | |
700 | 1 | |a You, Seng Chan |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Jin J |e verfasserin |4 aut | |
700 | 1 | |a Ryan, Patrick B |e verfasserin |4 aut | |
700 | 1 | |a Schuemie, Martijn J |e verfasserin |4 aut | |
700 | 1 | |a Krumholz, Harlan M |e verfasserin |4 aut | |
700 | 1 | |a Hripcsak, George |e verfasserin |4 aut | |
700 | 1 | |a Suchard, Marc A |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2024) vom: 08. Feb. |w (DE-627)NLM310900166 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:08 |g month:02 |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.02.05.24302354 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 08 |c 02 |